Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations (original) (raw)

Related papers

Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure

John Kjekshus

International Journal of Cardiology, 1984

View PDFchevron_right

Evaluation of a long-acting converting enzyme inhibitor (Enalapril) for the treatment of chronic congestive heart failure

Gary Schaer

Journal of the American College of Cardiology, 1983

View PDFchevron_right

Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure

Gerald Neuberg

The American Journal of Cardiology, 1991

View PDFchevron_right

Initial blood pressure response to enalapril in hospitalized patients (studies of left ventricular dysfunction [SOLVD])☆

Marston Youngblood

The American Journal of Cardiology, 1991

View PDFchevron_right

Hemodynamic and metabolic effects of enalapril in patients with heart failure

Iqbal Bal

Clinical Cardiology, 1985

View PDFchevron_right

Controlled trial of enalapril in congestive cardiac failure

Leonard Arnolda

Heart, 1985

View PDFchevron_right

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Carlos Flores

View PDFchevron_right

Angiotensin converting enzyme inhibitors in heart failure: how good are they?

Monir Ahmad

Heart, 1993

View PDFchevron_right

Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure

Luc Hittinger

Basic Research in Cardiology, 1999

View PDFchevron_right

A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients

Abul Basher

Journal of the American College of Cardiology, 2001

View PDFchevron_right

Tolerability of enalapril in congestive heart failure

Janet Rush

The American Journal of Cardiology, 1988

View PDFchevron_right

Comparative study of efficacy of Enalapril and Enalapril with Losartan in the management of Heart Failure

IOSR Journals

View PDFchevron_right

Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial

Bertram Pitt

European journal of heart failure, 2017

View PDFchevron_right

Evaluation of Angiotensin-Converting Enzyme Inhibitor in Congestive Heart Failure

Ratomir Jelic

Internal Medicine, 1996

View PDFchevron_right

Angiotensin converting enzyme inhibitors in congestive heart failure: Overview in comparison of captopril and enalapril

Irene Turpie

The American Journal of Medicine, 1986

View PDFchevron_right

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

Christian Hall

Journal of The American College of Cardiology, 1995

View PDFchevron_right

Short and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure

Thomas Giles

Journal of The American College of Cardiology, 1989

View PDFchevron_right

Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril)

Emanuel Bravo

Hypertension, 1984

View PDFchevron_right

Influence of angiotensin converting enzyme inhibition on pump function and cardiac contractility in patients with chronic congestive heart failure

J. Blokland

British heart journal, 1991

View PDFchevron_right

Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation

Hector Gomez

International Journal of Cardiology, 1986

View PDFchevron_right

Tolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction

Jeffrey Probstfield

American Heart Journal, 1994

View PDFchevron_right

Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: symptomatic cardiac obstruction–pilot study of enalapril in aortic stenosis (SCOPE-AS)

Venkatesan Sangareddi

American Heart Journal, 2004

View PDFchevron_right

Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors

Raquel Ascenção

Revista Portuguesa De Pneumologia, 2008

View PDFchevron_right

Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events

Ferenc Follath

The Journal of pharmacology and experimental therapeutics, 1999

View PDFchevron_right

Haemodynamic effects of enalapril, a new converting enzyme inhibitor, in hypertensive patients

Adalberto Urbina

European Journal of Clinical Pharmacology, 1985

View PDFchevron_right

Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study

George Alexopoulos

Journal of the American College of Cardiology, 2000

View PDFchevron_right

Comparison of Candesartan Enalapril and Their Combination in Congestive Heart Failure

Jeffrey Probstfield

2000

View PDFchevron_right

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators

Gilbert Gosselin

The American Heart Journal, 1996

View PDFchevron_right

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)

Jeffrey Probstfield

American Heart Journal, 1996

View PDFchevron_right